Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Q3 2021 · 10-Q
Revenue$10.93B$10.93B+23.4% vs Q3 2020 Net Income$2.10B$2.10B+70.5% vs Q3 2020 EPS Diluted$1.17$1.17+69.6% vs Q3 2020 Operating Income$2,546,000,000+70.3% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$2,240,000,000+42.7% Margins · derivedOperating margin23.3%+6.4 pt vs Q3 2020
Net margin19.2%+5.3 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 3, 2021 · 34 d after period end